facebook
twitter
rss
account
search
search
 

Supreme Court to take drug pricing case

Dec. 8, 2012 at 2:56 PM   |   Comments

WASHINGTON, Dec. 8 (UPI) -- The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.

The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.

The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.

"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.

Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.

The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.

© 2012 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Gazprom: Hungary ready for South Stream Gazprom: Hungary ready for South Stream
2
Poland, Pakistan, Lebanon seek U.S. military hardware Poland, Pakistan, Lebanon seek U.S. military hardware
3
Thales receives low-rate production contract for new assault rifle Thales receives low-rate production contract for new assault rifle
4
Report: Billionaires are hoarding mountains of cash
5
Canada decides to retire two guided missile destroyers Canada decides to retire two guided missile destroyers
Trending News
Video
x
Feedback